ICER Panel Agrees Aduhelm Is Overpriced, Has No Clinical Benefit

By Gabrielle Wanneh / July 16, 2021 at 8:11 PM
An expert panel convened by the Institute for Clinical and Economic Review unanimously agreed with ICER Thursday (July 15) that the newly approved Alzheimer’s drug Aduhelm is not worth the $56,000 list price set by manufacturer Biogen and has no net clinical benefit, coming as CMS launches a nine-month effort to decide whether to cover the drug and as some insurers and providers have already opted not to cover or prescribe the drug. Biogen has estimated that somewhere between 1...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.